表紙:特発性肺線維症(IPF)による咳嗽市場 - 市場の洞察、疫学、市場予測:2034年
市場調査レポート
商品コード
1415498

特発性肺線維症(IPF)による咳嗽市場 - 市場の洞察、疫学、市場予測:2034年

Cough in Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034

出版日: | 発行: DelveInsight | ページ情報: 英文 145 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
特発性肺線維症(IPF)による咳嗽市場 - 市場の洞察、疫学、市場予測:2034年
出版日: 2024年01月24日
発行: DelveInsight
ページ情報: 英文 145 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

特発性肺線維症(IPF)による咳嗽市場は予測期間(2023年~2034年)を通して安定した成長が見込まれます。新興治療法の上市により、IPFによる咳嗽の市場規模は主要7ヶ国で拡大すると予測されています。主要7ヶ国でIPFによる咳嗽と診断された有病者のうち、約51%が米国からの患者です。当社の予測では、2022年にはEU4ヶ国と英国がIPFによる咳嗽の診断有病者数約5万5,000人を占めています。

主要7ヶ国では、市場は主に神経調節薬、コルチコステロイド、その他の免疫調節薬で構成され、2022年には約1億5,400万米ドルを創出しました。

慢性咳嗽は特発性肺線維症(IPF)に多くみられ、しばしば初期症状として現れ、患者の生活に大きな影響を与えます。この持続的な咳嗽は、QOLの低下、抑うつや不安の増加、生理的障害の増加、疾患の進行と関連しています。慢性咳嗽の病態生理の完全な解明はいまだ困難であるが、最近の進歩により、その多因子性の性質が明らかにされつつあります。

IPFにおける慢性咳嗽の病態生理には、粘液産生とクリアランスの変化、肺組織の構造的歪み、咳反射の亢進など様々な要因が関与しています。IPF患者では、肺組織の構造が変化し、粘液を効果的に産生・排出する能力が損なわれている可能性があります。さらに、咳反射の亢進はIPFによる咳嗽の持続性の一因となります。咳嗽症状の重症度は全身の健康状態の低下と関連しており、しばしば疾患の進行を示します。

IPFによる咳嗽の診断には、臨床評価、肺機能検査(PFT)、高分解能コンピュータ断層撮影(HRCT)スキャンを含む包括的評価が必要です。場合によっては、気管支鏡検査で気道を調べ、分析用のサンプルを採取することもあります。集学的アプローチ、専門医間の連携、他の潜在的な原因の除外が不可欠です。

現在、IPFによる咳嗽の治療法として承認されているものはありません。IPFによる咳嗽の治療法は、咳嗽反射の抑制を目的とするものと、IPFの基礎病理を特異的に標的とするものに分けられます。残念ながら、咳反射の抑制を目的とした治療法の有効性は限られています。現在の治療法は、主に神経調節薬、副腎皮質ステロイド薬、その他の免疫調節薬に分類される適応外治療です。IPFにおける治療の欠如と高頻度の咳嗽は、患者のQOLに深刻な影響を与えます。

主要7ヶ国における特発性肺線維症(IPF)による咳嗽の市場規模は、2022年に1億5,400万米ドルとなりました。米国が2022年の市場を独占し、61%近くの最大シェアとなりました。EU4ヶ国と英国の市場規模は、2022年に4,500万米ドルとなりました。今後も高いCAGRで拡大すると予測されています。

当レポートでは、主要7ヶ国における特発性肺線維症(IPF)による咳嗽市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 特発性肺線維症(IPF)による咳嗽市場概要

第4章 IPFによる咳嗽の疫学と市場調査手法

第5章 IPFによる咳嗽のエグゼクティブサマリー

第6章 主要な出来事

第7章 疾患の背景と概要

  • イントロダクション
  • IPFの兆候と症状
  • IPFによる咳嗽
  • 慢性咳嗽の病態生理学
  • IPFによる咳嗽の病態生理学
  • IPFによる咳嗽のメカニズム
  • IPFによる咳嗽に影響を与える併存疾患
  • 診断
  • 治療
  • IPFによる咳嗽患者に対する一般的なアプローチ

第8章 疫学と患者数

  • 主な調査結果
  • IPFによる咳嗽の前提条件と理論的根拠:主要7ヶ国
  • 主要7ヶ国におけるIPFで診断された咳の罹患症例の合計
  • 米国
  • EU4ヶ国と英国
  • 日本

第9章 患者動向

第10章 新興薬剤

第11章 IPFによる咳嗽:市場分析

  • 主な調査結果
  • 主要な市場予測の前提条件
  • 市場の見通し
  • コンジョイント分析
  • 主要7ヶ国のIPFによる咳嗽の総市場規模
  • 主要7ヶ国のIPFによる咳嗽の市場規模、治療法別
  • 米国のIPFによる咳嗽の市場規模
  • EU4ヶ国および英国におけるIPFによる咳嗽の市場規模
  • 日本のIPFによる咳嗽の市場規模

第12章 主要なオピニオンリーダーの見解

第13章 SWOT分析

第14章 アンメットニーズ

第15章 市場アクセスと償還

  • 米国
  • EU4ヶ国と英国
  • 日本

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

図表

List of Tables

  • Table 1: Summary of Cough in IPF Epidemiology and Market (2020-2034)
  • Table 2: Key Events
  • Table 3: Assessment of Cough in IPF
  • Table 4: Interpretation of Strong and Conditional Recommendations for Stakeholders
  • Table 5: Comparison of Recommendations in 2015 and 2011 IPF Guidelines
  • Table 6: Total Diagnosed Prevalent Cases of Cough in IPF in the 7MM (2020-2034)
  • Table 7: Total Diagnosed Prevalent Cases of IPF in the US (2020-2034)
  • Table 8: Total Diagnosed Prevalent Cases of Cough in IPF in the US (2020-2034)
  • Table 9: Total Diagnosed Prevalent Cases of IPF in EU4 and the UK (2020-2034)
  • Table 10: Total Diagnosed Prevalent Cases of Cough in IPF in EU4 and the UK (2020-2034)
  • Table 11: Total Diagnosed Prevalent Cases of IPF in Germany (2020-2034)
  • Table 12: Total Diagnosed Prevalent Cases of Cough in IPF in Germany (2020-2034)
  • Table 13: Total Diagnosed Prevalent Cases of IPF in France (2020-2034)
  • Table 14: Total Diagnosed Prevalent Cases of Cough in IPF in France (2020-2034)
  • Table 15: Total Diagnosed Prevalent Cases of IPF in Italy (2020-2034)
  • Table 16: Total Diagnosed Prevalent Cases of Cough in IPF in Italy (2020-2034)
  • Table 17: Total Diagnosed Prevalent Cases of IPF in Spain (2020-2034)
  • Table 18: Total Diagnosed Prevalent Cases of Cough in IPF in Spain (2020-2034)
  • Table 19: Total Diagnosed Prevalent Cases of IPF in the UK (2020-2034)
  • Table 20: Total Diagnosed Prevalent Cases of Cough in IPF in the UK (2020-2034)
  • Table 21: Total Diagnosed Prevalent Cases of IPF in Japan (2020-2034)
  • Table 22: Total Diagnosed Prevalent Cases of Cough in IPF in Japan (2020-2034)
  • Table 23: Comparison of Emerging Drugs
  • Table 24: Orvepitant Maleate, Clinical Trial Description, 2024
  • Table 25: Haduvio (Nalbuphine ER), Clinical Trial Description, 2024
  • Table 26: Ifenprodil (NP-120), Clinical Trial Description, 2024
  • Table 27: ME-015 (Suplatast Tosilate), Clinical Trial Description, 2024
  • Table 28: Sodium pyruvate (N115), Clinical Trial Description, 2024
  • Table 29: Key Market Forecast Assumptions for Haduvio (nalbuphine ER)
  • Table 30: Key Market Forecast Assumptions for Orvepitant Maleate
  • Table 31: Total Market Size of Cough in IPF in the 7MM, in USD million (2020-2034)
  • Table 32: Market Size by Therapies of Cough in IPF in the 7MM, in USD million (2020-2034)
  • Table 33: Total Market Size of Cough in IPF in the US, in USD million (2020-2034)
  • Table 34: Market Size by Therapies of Cough in IPF in the US, in USD million (2020-2034)
  • Table 35: Total Market Size of Cough in IPF in EU4 and the UK, in USD million (2020-2034)
  • Table 36: Total Market Size of Cough in IPF in Germany, in USD million (2020-2034)
  • Table 37: Total Market Size of Cough in IPF in France, in USD million (2020-2034)
  • Table 38: Total Market Size of Cough in IPF in Italy, in USD million (2020-2034)
  • Table 39: Total Market Size of Cough in IPF in Spain, in USD million (2020-2034)
  • Table 40: Total Market Size of Cough in IPF in the UK, in USD million (2020-2034)
  • Table 41: Market Size by Therapies of Cough in IPF in EU4 and the UK, in USD million (2020-2034)
  • Table 42: Market Size by Therapies of Cough in IPF in Germany, in USD million (2020-2034)
  • Table 43: Market Size by Therapies of Cough in IPF in France, in USD million (2020-2034)
  • Table 44: Market Size by Therapies of Cough in IPF in Italy, in USD million (2020-2034)
  • Table 45: Market Size by Therapies of Cough in IPF in Spain, in USD million (2020-2034)
  • Table 46: Market Size by Therapies of Cough in IPF in the UK, in USD million (2020-2034)
  • Table 47: Total Market Size of Cough in IPF in Japan, in USD million (2020-2034)
  • Table 48: Market Size by Therapies of Cough in IPF in Japan, in USD million (2020-2034)

List of Figures

  • Figure 1: Signs and Symptoms of IPF
  • Figure 2: Pathophysiology of Cough
  • Figure 3: Mechanism of Cough in IPF
  • Figure 4: Interactions Between IPF, GORD, OSA, and cough.
  • Figure 5: Diagnostic Algorithm for IPF
  • Figure 6: Treatment practices for IPF
  • Figure 7: Therapeutic Algorithm of IPF
  • Figure 8: General Approach to Cough Patients in IPF
  • Figure 9: Total Diagnosed Prevalent Cases of Cough in IPF in the 7MM (2020-2034)
  • Figure 10: Total Diagnosed Prevalent Cases of IPF in the US (2020-2034)
  • Figure 11: Total Diagnosed Prevalent Cases of Cough in IPF in the US (2020-2034)
  • Figure 12: Total Diagnosed Prevalent Cases of IPF in EU4 and the UK (2020-2034)
  • Figure 13: Total Diagnosed Prevalent Cases of Cough in IPF in EU4 and the UK (2020-2034)
  • Figure 14: Total Diagnosed Prevalent Cases of IPF in Germany (2020-2034)
  • Figure 15: Total Diagnosed Prevalent Cases of Cough in IPF in Germany (2020-2034)
  • Figure 16: Total Diagnosed Prevalent Cases of IPF in France (2020-2034)
  • Figure 17: Total Diagnosed Prevalent Cases of Cough in IPF in France (2020-2034)
  • Figure 18: Total Diagnosed Prevalent Cases of IPF in Italy (2020-2034)
  • Figure 19: Total Diagnosed Prevalent Cases of Cough in IPF in Italy (2020-2034)
  • Figure 20: Total Diagnosed Prevalent Cases of IPF in Spain (2020-2034)
  • Figure 21: Total Diagnosed Prevalent Cases of Cough in IPF in Spain (2020-2034)
  • Figure 22: Total Diagnosed Prevalent Cases of IPF in the UK (2020-2034)
  • Figure 23: Total Diagnosed Prevalent Cases of Cough in IPF in the UK (2020-2034)
  • Figure 24: Total Diagnosed Prevalent Cases of IPF in Japan (2020-2034)
  • Figure 25: Total Diagnosed Prevalent Cases of Cough in IPF in Japan (2020-2034)
  • Figure 26: Patient Journey of Cough in IPF
  • Figure 27: Total Market Size of Cough in IPF in the 7MM, in USD million (2020-2034)
  • Figure 28: Market Size by Therapies of Cough in IPF in the 7MM, in USD million (2020-2034)
  • Figure 29: Total Market Size of Cough in IPF in the US, in USD million (2020-2034)
  • Figure 30: Market Size by Therapies of Cough in IPF in the US, in USD million (2020-2034)
  • Figure 31: Total Market Size of Cough in IPF in EU4 and the UK, in USD million (2020-2034)
  • Figure 32: Total Market Size of Cough in IPF in Germany, in USD million (2020-2034)
  • Figure 33: Total Market Size of Cough in IPF in France, in USD million (2020-2034)
  • Figure 34: Total Market Size of Cough in IPF in Italy, in USD million (2020-2034)
  • Figure 35: Total Market Size of Cough in IPF in Spain, in USD million (2020-2034)
  • Figure 36: Total Market Size of Cough in IPF in the UK, in USD million (2020-2034)
  • Figure 37: Market Size by Therapies of Cough in IPF in EU4 and the UK, in USD million (2020-2034)
  • Figure 38: Market Size by Therapies of Cough in IPF in Germany, in USD million (2020-2034)
  • Figure 39: Market Size by Therapies of Cough in IPF in France, in USD million (2020-2034)
  • Figure 40: Market Size by Therapies of Cough in IPF in Italy, in USD million (2020-2034)
  • Figure 41: Market Size by Therapies of Cough in IPF in Spain, in USD million (2020-2034)
  • Figure 42: Market Size by Therapies of Cough in IPF in the UK, in USD million (2020-2034)
  • Figure 43: Total Market Size of Cough in IPF in Japan, in USD million (2020-2034)
  • Figure 44: Market Size by Therapies of Cough in IPF in Japan, in USD million (2020-2034)
  • Figure 45: SWOT Analysis
  • Figure 46: Unmet Needs
  • Figure 47: Health Technology Assessment
  • Figure 48: Reimbursement Process in Germany
  • Figure 49: Reimbursement Process in France
  • Figure 50: Reimbursement Process in Spain
  • Figure 51: Reimbursement Process in the United Kingdom
  • Figure 52: Reimbursement Process in Japan
目次
Product Code: DIMI1645

Key Highlights:

  • The Cough in IPF market is projected to witness consistent growth throughout the forecast period (2023-2034). The market size of Cough in IPF in the 7MM is expected to increase, driven by the launch of emerging therapies.
  • DelveInsight's analyst projects that among the total diagnosed prevalent cases of Cough in IPF in 7MM approximately 51% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 55 thousand diagnosed prevalent cases of Cough in IPF.
  • In the 7MM, the market mainly consisted of neuromodulators, corticosteroids, and other immunomodulatory agents which generated nearly USD 154 million in 2022.
  • The total market size of the Cough in IPF treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Orvepitant Maleate and Haduvio (nalbuphine).

DelveInsight's "Cough in Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Cough in IPF, historical and forecasted epidemiology and the Cough in IPF market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Cough in IPF market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Cough in IPF market size from 2020 to 2034. The report also covers current Cough in IPF treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034.

Disease Understanding and Treatment Algorithm

Cough in IPF Overview

Chronic cough is prevalent in idiopathic pulmonary fibrosis (IPF), often presenting as the initial symptom and significantly impacting patients' lives. This persistent cough is associated with diminished quality of life, heightened rates of depression and anxiety, increased physiological impairment, and disease progression. While the complete understanding of its pathophysiology remains elusive, recent advancements shed light on its multifactorial nature.

The pathophysiology of chronic cough in IPF involves various factors, including alterations in mucous production and clearance, architectural distortion of lung tissues, and heightened sensitivity of the cough reflex. Patients with IPF may experience architectural changes in lung tissues, impairing their ability to produce and clear mucous effectively. Additionally, an increased sensitivity of the cough reflex contributes to the persistent nature of cough in IPF. The severity of cough symptoms is linked to a decline in overall health and is often indicative of disease progression.

Cough in IPF Diagnosis

The diagnosis of cough in IPF involves a comprehensive evaluation, including clinical assessment, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) scans. In some cases, bronchoscopy may be utilized to examine the airways and collect samples for analysis. A multidisciplinary approach, collaboration among specialists, and the exclusion of other potential causes are integral.

Cough in IPF Treatment

Currently, there is no known approved treatment of cough in IPF. Therapies for cough in IPF can be divided into those that aim to suppress the cough reflex and those that specifically target the underlying pathology of IPF. Unfortunately, treatments aimed at suppressing the cough reflex have limited efficacy. The current treatment landscape consists of off-label therapies mainly classified as neuromodulating agents, corticosteroids, and other immunomodulatory agents. The lack of treatment and high frequency of cough in IPF severely impacts the quality of life of the patients.

Cough in IPF Epidemiology

As the market is derived using the patient-based model, the Cough in IPF epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of IPF and Total Diagnosed Prevalent Cases of Cough in IPF, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per DelveInsight's estimations, the total diagnosed prevalent cases of Cough in IPF in the 7MM were approximately 148 thousand cases in 2022 and are projected to increase during the forecast period.

  • The overall count of individuals diagnosed with IPF in the United States was approximately 95 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
  • Among the 7MM, the US accounted for nearly 76 thousand diagnosed prevalent cases of Cough in IPF, and these cases are expected to increase during the forecast period (2023-2034).
  • Among EU4 and the UK, the UK had the highest diagnosed prevalent population of Cough in IPF, with about 13 thousand cases, followed by France and Italy in 2022. On the other hand, Germany had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
  • In Japan, there were around 17 thousand diagnosed prevalent cases of Cough in IPF in 2022. These cases are expected to increase at a significant CAGR.

Cough in IPF Drug Chapters

The drug chapter segment of the Cough in IPF report encloses a detailed analysis of Cough in IPF marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Cough in IPF clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs:

Orvepitant Maleate: NeRRe Therapeutics

Orvepitant Maleate, developed by NeRRe Therapeutics, is a novel, selective NK-1 receptor antagonist. It blocks substance P effects, reducing central neural hypersensitivity and addressing chronic cough through peripherally and centrally targeted mechanisms. After demonstrating proof of efficacy in patients with RCC or UCC, NeRRe is currently conducting Phase II trials to evaluate the effect of two doses of orvepitant in chronic cough with IPF.

Haduvio (nalbuphine ER): Trevi Therapeutics

Haduvio (nalbuphine ER) is under clinical development by Trevi Therapeutics and is currently in Phase II for cough in IPF treatment. Administered orally, it is an extended-release, mixed ?-opioid receptor agonist and µ-opioid receptor antagonist.

Note: Detailed emerging therapies assessment will be provided in the final report of Cough in IPF.

Cough in IPF Market Outlook

Cough, a predominant and distressing symptom in IPF, significantly compromises patients' quality of life, prompting a pressing need for effective interventions tailored to this aspect of the disease. Despite approved therapies for IPF, there is not an established treatment specifically targeting the associated cough.

Current therapeutic strategies for IPF-related cough fall into two categories: those suppressing the cough reflex and those targeting IPF pathology. Yet, agents like dextromethorphan and opioids exhibit limited efficacy and systemic side effects, hindering widespread use. Traditional IPF medications, pirfenidone and nintedanib, mainly focus on disease progression without extensive studies on managing IPF-related cough.

The IPF-related cough treatment market emphasizes the need for targeted therapies. Ongoing research in neuromodulating agents, immunomodulators, and behavior-based therapies holds promise, but comprehensive studies are needed to develop effective treatments, enhancing the quality of life for those affected by this challenging symptom.

The market for Cough in IPF is expected to experience positive growth with the approval of potential drugs like Orvepitant Maleate and Haduvio (nalbuphine ER).

  • The Cough in IPF market's total size in the 7MM reached approximately USD 154 million in 2022. Projections indicate a substantial growth during the forecast period.
  • Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 61%.
  • In 2022, EU4 and the UK captured an estimated USD 45 million, which is anticipated to increase at a substantial CAGR. Among the European countries, the UK covered the largest market share in 2022, followed by France, Italy and Spain. Germany accounted for the least market in the same year.
  • Japan alone represented approximately 10% of the total Cough in IPF market in 2022, projected to increase at a substantial CAGR during the study period.
  • The total market size of the Cough in IPF treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Cough in IPF Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Haduvio (nalbuphine ER) in the US is expected to be launched by 2028.

Further detailed analysis of emerging therapies drug uptake in the report…

Cough in IPF Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Cough in IPF emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Cough in IPF evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Albert Einstein College of Medicine, New York; Keck School of Medicine, University of Southern California, Los Angeles; Ruhrlandklinik, University Hospital Essen, Essen, Germany; Louis Pradel Hospital, Hospices Civils de Lyon, France; University of Milano Bicocca, Italy; Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; Graduate School of Medicine, Kyoto University, Kyoto, Japan, and others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Cough in IPF market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

  • The report covers a segment of key events, an executive summary, descriptive overview of Cough in IPF, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
  • Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
  • A detailed review of the Cough in IPF market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Cough in IPF market.

Cough in IPF Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cough in IPF Pipeline Analysis
  • Cough in IPF Market Size and Trends
  • Existing and Future Market Opportunity

Cough in IPF Report Key Strengths

  • 12 years Forecast
  • The 7MM Coverage
  • Cough in IPF Epidemiology Segmentation
  • Key Cross Competition
  • Conjoint Analysis
  • Drugs Uptake and Key Market Forecast Assumptions

Cough in IPF Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

  • What was the Cough in IPF total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
  • What unmet needs are associated with the current treatment market of Cough in IPF?
  • What are the patents of emerging therapies for Cough in IPF?
  • Which drug is going to be the largest contributor by 2034?
  • What are the pricing variations among different geographies for approved and off-label therapies?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

  • What are the disease risks, burdens, and unmet needs of Cough in IPF? What will be the growth opportunities across the 7MM concerning the patient population of Cough in IPF?
  • What is the historical and forecasted Cough in IPF patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
  • Why do only limited patients appear for diagnosis?
  • Which country is more prevalent for Cough in IPF and why?
  • What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What are the current options for treating Cough in IPF? What are the current guidelines for treating Cough in IPF in the US and Europe?
  • How many companies are developing therapies for treating Cough in IPF?
  • How many emerging therapies are in the mid-stage and late stage of development for treating Cough in IPF?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
  • What are the key designations that have been granted for the emerging therapies for Cough in IPF?
  • Patient acceptability in terms of preferred treatment options as per real-world scenarios?
  • What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
  • What are the 7MM historical and forecasted markets of Cough in IPF?

Reasons to Buy:

  • The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Cough in IPF Market.
  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
  • Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
  • Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
  • To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Cough in IPF Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Cough in IPF market?

The Cough in IPF emerging market has few drugs. The major key players developing therapies for cough in IPF are Trevi Therapeutics, NeRRe Therapeutics, and others.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Cough in IPF market?

The increase in diagnosed prevalent cases of Cough in IPF and the launch of emerging therapies are attributed to be the key drivers for increasing Cough in IPF market.

5. What is the expected impact of emerging therapies or advancements in Cough in IPF treatment on the market?

Introducing new therapies, advancements in disease understanding and diagnostic techniques, and innovations in treatment approaches can significantly impact the Cough in IPF treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Cough in IPF market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Cough in Idiopathic pulmonary fibrosis (IPF) Market Overview at a Glance

  • 3.1. Market Share (%) Distribution by Therapies of Cough in IPF in 2020
  • 3.2. Market Share (%) Distribution by Therapies of Cough in IPF in 2034

4. Epidemiology and Market Methodology of Cough in IPF

5. Executive Summary of Cough in IPF

6. Key Events

7. Disease Background and Overview

  • 7.1. Introduction
  • 7.2. Signs and Symptoms of IPF
  • 7.3. Cough in IPF
  • 7.4. Pathophysiology of Chronic Cough
  • 7.5. Pathophysiology of Cough in IPF
  • 7.6. Mechanism of Cough in IPF
  • 7.7. Comorbidities influencing cough in IPF
  • 7.8. Diagnosis
    • 7.8.1. Diagnostic Algorithm
    • 7.8.2. Diagnostic Guideline
      • 7.8.2.1. ATS-ERS-JRS-ALAT Recommendations Made for the Diagnosis of IPF
  • 7.9. Treatment
    • 7.9.1. Treatment of IPF
    • 7.9.2. Treatment of Cough in IPF
    • 7.9.3. Treatment Algorithm
    • 7.9.4. Treatment Guidelines
      • 7.9.4.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
      • 7.9.4.2. French Practical Guidelines for the Diagnosis and Management of Idiopathic Pulmonary Fibrosis (2017)
      • 7.9.4.3. NICE Guidelines on Idiopathic Pulmonary Fibrosis in Adults: Diagnosis and Management (2017)
  • 7.10. General Approach to Cough Patients in IPF

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Assumption and Rationale of Cough in IPF: The 7MM
  • 8.3. Total Diagnosed Prevalent Cases of Cough in IPF in the 7MM
  • 8.4. The United States
    • 8.4.1. Total Diagnosed Prevalent Cases of IPF in the US
    • 8.4.2. Total Diagnosed Prevalent Cases of Cough in IPF in the US
  • 8.5. EU4 and the UK
    • 8.5.1. Germany
      • 8.5.1.1. Total Diagnosed Prevalent Cases of IPF in Germany
      • 8.5.1.2. Total Diagnosed Prevalent Cases of Cough in IPF in Germany
    • 8.5.2. France
      • 8.5.2.1. Total Diagnosed Prevalent Cases of IPF in France
      • 8.5.2.2. Total Diagnosed Prevalent Cases of Cough in IPF in France
    • 8.5.3. Italy
      • 8.5.3.1. Total Diagnosed Prevalent Cases of IPF in Italy
      • 8.5.3.2. Total Diagnosed Prevalent Cases of Cough in IPF in Italy
    • 8.5.4. Spain
      • 8.5.4.1. Total Diagnosed Prevalent Cases of IPF in Spain
      • 8.5.4.2. Total Diagnosed Prevalent Cases of Cough in IPF in Spain
    • 8.5.5. The United Kingdom
      • 8.5.5.1. Total Diagnosed Prevalent Cases of IPF in the UK
      • 8.5.5.2. Total Diagnosed Prevalent Cases of Cough in IPF in the UK
  • 8.6. Japan
    • 8.6.1. Total Diagnosed Prevalent Cases of IPF in Japan
    • 8.6.2. Total Diagnosed Prevalent Cases of Cough in IPF in Japan

9. Patient Journey

10. Emerging Therapies

  • 10.1. Key Cross Competition of Emerging Drugs
  • 10.2. Orvepitant Maleate: NeRRe Therapeutics
    • 10.2.1. Product Description
    • 10.2.2. Other Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Clinical Trial Information
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
    • 10.2.7. Analysts' Views
  • 10.3. Haduvio (Nalbuphine ER): Trevi Therapeutics
    • 10.3.1. Product Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Clinical Trials Information
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile
    • 10.3.7. Analysts' Views
  • 10.4. Ifenprodil (NP-120): Algernon Pharmaceuticals/Seyltx Inc.
    • 10.4.1. Product Description
    • 10.4.2. Other Developmental Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Clinical Trials Information
    • 10.4.5. Safety and Efficacy
    • 10.4.6. Product Profile
    • 10.4.7. Analysts' Views
  • 10.5. ME-015 (Suplatast Tosilate): Melius Pharma AB
    • 10.5.1. Product Description
    • 10.5.2. Other Development Activities
    • 10.5.3. Clinical Development
    • 10.5.4. Clinical Trial Information
    • 10.5.5. Product Profile
    • 10.5.6. Analysts' Views
  • 10.6. Sodium pyruvate (N115): Cellular Sciences/Emphycorp
    • 10.6.1. Product Description
    • 10.6.2. Other Development Activities
    • 10.6.3. Clinical Development
    • 10.6.4. Clinical Trial Information
    • 10.6.5. Product Profile
    • 10.6.6. Analysts' Views

11. Cough in IPF: Market Analysis

  • 11.1. Key Findings
  • 11.2. Key Market Forecast Assumptions
  • 11.3. Market Outlook
  • 11.4. Conjoint Analysis
  • 11.5. Total Market Size of Cough in IPF in the 7MM
  • 11.6. Market Size of Cough in IPF by Therapies in the 7MM
  • 11.7. Market Size of Cough in IPF in the United States
    • 11.7.1. Total Market Size of Cough in IPF
    • 11.7.2. Market Size by Therapies of Cough in IPF in the United States
  • 11.8. Market Size of Cough in IPF in EU4 and the UK
    • 11.8.1. Germany
      • 11.8.1.1. Total Market Size of Cough in IPF
      • 11.8.1.2. Market Size by Therapies of Cough in IPF in Germany
    • 11.8.2. France
      • 11.8.2.1. Total Market Size of Cough in IPF
      • 11.8.2.2. Market Size by Therapies of Cough in IPF in France
    • 11.8.3. Italy
      • 11.8.3.1. Total Market Size of Cough in IPF
      • 11.8.3.2. Market Size by Therapies of Cough in IPF in Italy
    • 11.8.4. Spain
      • 11.8.4.1. Total Market Size of Cough in IPF
      • 11.8.4.2. Market Size by Therapies of Cough in IPF in Spain
    • 11.8.5. The United Kingdom
      • 11.8.5.1. Total Market Size of Cough in IPF
      • 11.8.5.2. Market Size by Therapies of Cough in IPF in the UK
  • 11.9. Market Size of Cough in IPF in Japan
    • 11.9.1. Total Market Size of Cough in IPF
    • 11.9.2. Market Size by Therapies of Cough in IPF in Japan

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

  • 15.1. The United States
    • 15.1.1. Center for Medicare and Medicaid Services (CMS)
  • 15.2. In EU4 and the UK
    • 15.2.1. Germany
    • 15.2.2. France
    • 15.2.3. Italy
    • 15.2.4. Spain
    • 15.2.5. The United Kingdom
  • 15.3. Japan
    • 15.3.1. MHLW

16. Appendix

  • 16.1. Bibliography
  • 16.2. Acronyms and Abbreviations
  • 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer